RAMP1 and migraine disorder: The novel anti-migraine drugs targeting the canonical CGRP receptor (i.e. gepants and the monoclonal antibody erenumab) are designed to target the hydrophobic pocket between CLR and RAMP1, thereby preventing direct binding of CGRP to the receptor [23, 24].